Digest Network How does it work
Network
/
Society
Ag
Not verified

Agenus Inc.

What we write about

BiotechnologyHealthMedicine - variousOncologyPharmaceuticals

84 Press releases

View all press releases
09/10/2026
Eventi
WEB AND SOCIAL NETWORK
Biotechnology
Pharmaceuticals
Health
Oncology
Agenus to Participate in Chardan’s 10th Annual Healthcare Investor Conference
Source
Agenus Inc.
Issuer
Business Wire
1.00
0
08/10/2026
Eventi
Industria
Oncology
Health
Medicine - various
Scienza
Pharmaceuticals
Biotechnology
Armenia Grants First Marketing Authorizations for Agenus’ BOT+BAL in Previously Treated MSS Metastatic Colorectal Cancer
Source
Agenus Inc.
Issuer
Business Wire
1.00
0
03/10/2026
Biotechnology
Health
Pharmaceuticals
Medicine - various
Oncology
Eventi
Industria
Agenus Reports 48% Estimated Three-Year Survival With BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Source
Agenus Inc.
Issuer
Business Wire
1.00
0
02/10/2026
Eventi
Industria
Biotechnology
Health
Pharmaceuticals
Medicine - various
Oncology
Agenus to Present BOT+BAL Long-Term Survival Data and Translational Research With agenT-797 in Colorectal Cancer at SITC 2026
Source
Agenus Inc.
Issuer
Business Wire
1.00
0
10/09/2026
Eventi
Industria
Biotechnology
Health
Pharmaceuticals
Medicine - various
Oncology
Agenus to Present Three-Year Overall Survival Data for BOT+BAL in Recurrent Ovarian Cancer at IGCS 2026
Source
Agenus Inc.
Issuer
Business Wire
1.00
0
31/08/2026
Eventi
WEB AND SOCIAL NETWORK
Biotechnology
Health
Pharmaceuticals
Medicine - various
Oncology
Agenus to Participate in Upcoming September Investor Conferences
Source
Agenus Inc.
Issuer
Business Wire
1.00
0
28/08/2026
Eventi
Industria
Oncology
Health
Medicine - various
Scienza
Pharmaceuticals
Biotechnology
Agenus Announces Peer-Reviewed Publication Linking BOT+BAL’s Durable Survival in MSS Metastatic Colorectal Cancer to Its Distinct Immune-Priming Mechanism
Source
Agenus Inc.
Issuer
Business Wire
1.00
0
26/08/2026
Eventi
Industria
Scienza
Biotechnology
Pharmaceuticals
Oncology
Health
Medicine - various
Agenus Announces Updated NEST Phase 2 Publication Reporting Deep Pathologic Responses and No Observed Recurrences with Neoadjuvant BOT+BAL in Resectable Colon Cancer
Source
Agenus Inc.
Issuer
Business Wire
1.00
0
06/08/2026
WEB AND SOCIAL NETWORK
Phones and Miscellaneous
stock market
Biotechnology
Pharmaceuticals
Health
Oncology
Agenus Reports Second Quarter 2026 Results and Advances Phase 3 ROBBIN Trial of BOT+BAL in Neoadjuvant MSS Colon Cancer
Source
Agenus Inc.
Issuer
Business Wire
1.00
0
28/07/2026
WEB AND SOCIAL NETWORK
Finance
stock market
Biotechnology
Health
Pharmaceuticals
Medicine - various
Oncology
Agenus to Provide Second Quarter 2026 Financial Report and Development Update
Source
Agenus Inc.
Issuer
Business Wire
1.00
0

Contact details

Social Media

Followers
0
Compatibility
0